BACKGROUND Portal vein tumor thrombus(PVTT)is a common complication,accounting for 44%-62.2%of Hepatocellular carcinoma(HCC),and often indicates the poor prognosis.There is no global consensus for the treatment of unr...BACKGROUND Portal vein tumor thrombus(PVTT)is a common complication,accounting for 44%-62.2%of Hepatocellular carcinoma(HCC),and often indicates the poor prognosis.There is no global consensus for the treatment of unresectable HCC with PVTT.In the present case,we reported a novel strategy of radiotherapyantiangiogenesis-immune checkpoint blockade combination,which showed better response and prolonged survival.CASE SUMMARY A 51-year-old male diagnosed with HCC(Child-Pugh class A),chronic hepatitis B virus infection and Cheng’s type III PVTT,was given radiotherapy to part of the lesion plus targeted therapy as the first-line therapy,and achieved partial remission.After radiotherapy,lenvatinib plus pembrolizumab was used as maintenance therapy,and complete remission was achieved.The patient remains alive 46 months after the diagnosis of the HCC with PVTT.CONCLUSION This case of unresectable HCC patient with PVTT treated by radiation-lenvatinibpembrolizumab combination therapy shows apparent clinical efficacy,which demonstrates that local radiotherapy plus antiangiogenesis and immune checkpoint blockad could also benefit patients with advanced HCC.展开更多
文摘BACKGROUND Portal vein tumor thrombus(PVTT)is a common complication,accounting for 44%-62.2%of Hepatocellular carcinoma(HCC),and often indicates the poor prognosis.There is no global consensus for the treatment of unresectable HCC with PVTT.In the present case,we reported a novel strategy of radiotherapyantiangiogenesis-immune checkpoint blockade combination,which showed better response and prolonged survival.CASE SUMMARY A 51-year-old male diagnosed with HCC(Child-Pugh class A),chronic hepatitis B virus infection and Cheng’s type III PVTT,was given radiotherapy to part of the lesion plus targeted therapy as the first-line therapy,and achieved partial remission.After radiotherapy,lenvatinib plus pembrolizumab was used as maintenance therapy,and complete remission was achieved.The patient remains alive 46 months after the diagnosis of the HCC with PVTT.CONCLUSION This case of unresectable HCC patient with PVTT treated by radiation-lenvatinibpembrolizumab combination therapy shows apparent clinical efficacy,which demonstrates that local radiotherapy plus antiangiogenesis and immune checkpoint blockad could also benefit patients with advanced HCC.
